FDA approves Novo Nordisk Awiqli as first once-weekly basal insulin for children with type 2 diabetes

The FDA has expanded Novo Nordisk's Awiqli approval to children aged 10 years and older with type 2 diabetes, establishing the first once-weekly basal insulin option for this paediatric population.
Awiqli (insulin icodec-abae) is now authorised as a once-weekly subcutaneous basal insulin for eligible children with type 2 diabetes as an adjunct to diet and exercise, extending its previously approved adult indication.
The paediatric decision was supported by pharmacokinetic data from 18 patients and pharmacometric modelling, providing an additional insulin administration option that may reduce injection frequency compared with daily basal insulin regimens.
Field | Content |
Article Type | Approvals |
Regulatory Authority | U.S. Food and Drug Administration |
Regulatory Decision | Paediatric indication expansion |
Approval Announcement Date | 23 October 2026 |
Company | Novo Nordisk |
Drug Name | Awiqli |
Generic Name | Insulin icodec-abae |
Drug Class | Long-acting basal insulin |
Therapeutic Area | Endocrinology; diabetes |
Approved Indication | Type 2 diabetes mellitus in children aged 10 years and older as an adjunct to diet and exercise |
Patient Population | Paediatric patients aged 10 years and older with type 2 diabetes |
Administration Route | Subcutaneous injection |
Dosing Frequency | Once weekly |
Regulatory Significance | First once-weekly insulin approved for paediatric type 2 diabetes in the United States |
Previous Approved Population | Adults with type 2 diabetes |
Supporting Evidence | Paediatric pharmacokinetic data and pharmacometric modelling |
Paediatric Pharmacokinetic Study Population | 18 patients |
Comparative Efficacy Results | Not provided in supplied summary |
Geography | United States |
What Happened | The FDA expanded Awiqli's approved use to children aged 10 years and older with type 2 diabetes. |
Why It Matters | The decision introduces a once-weekly basal insulin option for eligible paediatric patients and may reduce treatment administration burden. |
Clinical Evidence | The paediatric approval was supported by pharmacokinetic observations in 18 patients and pharmacometric modelling. |
Regulatory Distinction | This is a new paediatric indication rather than a repeat of the existing adult approval. |
Key Takeaway | Awiqli is the first FDA-approved once-weekly basal insulin for children aged 10 years and older with type 2 diabetes. |
What to Watch | Updated paediatric prescribing guidance, dosing implementation, clinician adoption, reimbursement and real-world safety outcomes. |
Primary Source | U.S. Food and Drug Administration |
Primary Source URL | https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-once-weekly-insulin-type-2-diabetes-mellitus-pediatric-patients |
Relevant Date | 23 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

コメント